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A B S T R A C T
Background: To investigate the potential correlation of neutrophil/lymphocyte ratio (NLR) to coronary
blood ﬂow and in-hospital along with long-term mortality in patients with ST-elevation myocardial
infarction (STEMI) undergoing percutaneous coronary intervention (PCI).
Methods: In the current study, 636 consecutive patients with STEMI were recruited and stratiﬁed into
three tertiles by NLRs upon admission (tertile I < 3.0, tertile II 3.0–6.40, tertile III > 6.40). The coronary
blood ﬂow was expressed by corrected TIMI frame count (CTFC). The in-hospital mortality and 12-
month long follow-up data were collected. Receiver operating characteristic (ROC) curves were also
constructed.
Results: Our analysis demonstrated that NLR was positively correlated to CTFC and in-hospital mortality
(r = 0.517, p < 0.001; r = 0.439, p < 0.001). In the multiple logistic regression analysis, NLR was testiﬁed
as an independent risk factor for coronary blood ﬂow after PCI and in-hospital mortality [odds ratio
(OR) = 2.031, 95% conﬁdence interval (CI): 1.627–2.435, p < 0.001; OR = 1.176, 95% CI: 1.025–1.351,
p = 0.021]. During the 12-month follow-up, there were a total of 43 deaths and statistically signiﬁcant
increase in long-term mortality was observed in patients from tertile I to III (p = 0.005). In the ROC curves
analysis, the area under the curve (AUC = 0.607, 95% CI: 0.475–0.739, p = 0.253), with threshold value of
5.9 (sensitivity: 63.7%, speciﬁcity: 61.1%) for predicting in-hospital mortality.
Conclusions: NLR, an indicator that can be tested in the laboratory with low cost and time consumption,
is independently correlated to coronary blood ﬂow and acts as an independent risk factor for in-hospital
mortality in patients with STEMI undergoing PCI.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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As one of the diseases with high morbidity and mortality in the
world, cardiovascular disease (CVD), especially acute myocardial
infarction (AMI) has a serious impact on life expectancy and life
quality of human beings [1]. AMI is usually due to ischemia of the
myocardium caused by coronary artery occlusion. The main
diagnosis of AMI is by electrocardiogram (ECG) while ST-elevation
myocardial infarction (STEMI) is necrosis of the myocardial tissue
caused by total occlusion of a coronary artery, which can be* Corresponding author at: Department of Cardiology, The First Afﬁliated
Hospital of Harbin Medical University, Nangang District, Heilongjiang Province
23, Harbin 150001, China. Tel.: +86 0451 85555707; fax: +86 0451 87530341.
E-mail address: LanfengWanglfw@163.com (L. Wang).
http://dx.doi.org/10.1016/j.jjcc.2014.10.014
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsindicated by persistent elevation of the ST-segment on ECG. As for
prognosis, scoring systems such as the thrombolysis in myocardial
infarction (TIMI) score [2], the Platelet glycoprotein IIb/IIIa in
Unstable agina: Receptor Suppression Using Integrilin (PURSUIT)
score [3], and the Global Registry of Acute Coronary Events (GRACE)
score [4] have been adopted to allow clinicians to stratify risk
of disease. There is still a lack of prognostic biomarkers to
complement the prognostic value of the simple risk scores and
the only accepted one is cardiac troponin [5]. It has been well
documented that atherosclerosis is the pathological basis of AMI
and inﬂammation plays an important role in the indication and
progression of atherosclerosis [6,7]. Given the association of
inﬂammation with AMI, we should devote much effort to discover
AMI-associated inﬂammatory markers. Neutrophil to lymphocyte
ratio (NLR) is a widely used inﬂammatory marker and its linkage to reserved.
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elevated NLR was reported to have implications in long-term
mortality as well as impaired coronary arteries in patients with
AMI [10–15]. Here in the current study, by recruiting a large sample
size with 12 months of clinical follow-up, we have systematically
determined the association of NLR with coronary blood ﬂow as
well as in-hospital and long-term mortality in patients with STEMI
undergoing percutaneous coronary intervention (PCI).
Materials and methods
Ethical statement
Informed written consent was obtained from all patients
involved in the study. All protocols involving human subjects were
approved by the local Ethics Committee.
Study population
A total number of 636 consecutive patients with the diagnosis
of STEMI (78% male, mean age 59.27  11.27 years) admitted to the
First Afﬁliated Hospital of Harbin Medical University from January
2008 to September 2011 were recruited. STEMI was deﬁned as typical
chest pain  30 min with ST-segment elevation > 1 mm in 2
consecutive leads on ECG or new-onset left bundle brunch block.
Exclusion criteria included treatment with thrombolytic drugs in
previous 24 h, active infections, previously proved systemic inﬂam-
matory disease, patients with shock or old myocardial infarction, or
with history of PCI/coronary artery bypass grafting, cancer, end-stage
liver or renal failure, rheumatoid immune system disease, and recent
use of steroid drugs. Detailed information on all patients was also
collected, including medical history as well as results from physical
examination and the laboratory examination (i.e. routine blood test,
routine urine test, biochemical series, ECG, transthoracic echocardi-
ography).
NLR calculation
The blood sample was taken immediately after admission and
sent for laboratory analysis. The white blood cell (WBC) count as
well as subtypes was measured by automatic blood cell analyzer
(Ruby, Abbott Laboratories, Abbott Park, IL, USA). NLR was
obtained via dividing neutrophil count by lymphocyte count.
PCI procedure and echocardiography
The standard femoral approach with a 7-French guiding
catheter was adopted to perform all primary PCI, as previously
described [16]. The patients were ﬁrst injected intravenously with
5000 IU of heparin (70 U/kg) and a 300 mg loading dose of both
aspirin and clopidogrel, and then direct stenting or balloon pre-
dilatation was performed. The operator determined the choice of
stents (bare metal or drug-eluting stent). Transthoracic echocar-
diography was performed with standard echocardiography pro-
cedure using the iE33 xMATRIX Echocardiography System (Philips,
Andover, MA, USA) for each patient immediately following PCI in
the intensive cardiac care unit. The PCI procedure was successfully
performed with all the patients, and stents were successfully
implanted with all the patients. The information on patients about
the duration (hour) from symptom onset to recanalization with
each group was recorded.
Measurement of coronary blood ﬂow
In the present study, coronary blood ﬂow was calculated by the
corrected TIMI frame count (CTFC) which was assessed by threeindependent interventional doctors, and the CTFC was measured at
90–120 min after thrombolytic administration. In addition, nicor-
andil or nitroprusside was injected into coronary artery if the
coronary ﬂow was slow after ballooning. The ﬁrst and last frames
used for TIMI frame counting were deﬁned as follows: in the ﬁrst
frame, contrast medium fully entered the artery and there must be
antegrade motion, while in the last frame, contrast medium went
into the marked target artery distal branch. The branch of the left
anterior descending coronary artery (LAD) used for TIMI frame
counting was determined as follows: the distal-most branch in the
LAD (also referred to as the ‘‘pitchfork,’’ ‘‘mustache,’’ or ‘‘whale’s
tail’’) usually occurred at the apex of the heart. In a wraparound
LAD, the branch closest to the apex of the heart was used. The
branch of the left circumﬂex (LCX) used for TIMI frame counting
was determined as follows: the artery used for TIMI frame
counting was the artery with the longest total distance along
which contrast medium traveled in the LCX system but yet passed
through the culprit lesion. The branch of the right coronary artery
(RCA) used for TIMI frame counting was determined as follows: the
distal landmark was the ﬁrst branch arising from the posterior
lateral extension of the RCA after the origin of the posterior
descending artery, regardless of the size of this branch. Count of the
anterior descending and circumﬂex selected the right anterior
oblique plus foot. Count of the right coronary artery selected left
anterior oblique position plus head. The left LAD was longer than
the mean of the RCA and LCX. Therefore, the longer LAD frame
counts were corrected via dividing by 1.7 to derive CTFC [17].
Follow-up data collection
In-hospital mortality was obtained for all subjects based on
hospital records. Survival data post hospital discharge were
obtained by a 12-month in person or telephone interview with
patients, families, or primary physicians.
Statistical analysis
Patients were categorized into tertiles on the basis of NLR as
previously described [11,14]. Continuous variables were tested for
normal distribution by Kolmogorov–Smirnov test. Continuous data
were presented as mean  SD and Student’s t test and Mann–Whitney
U test were adopted for statistical comparisons between two groups for
normally and abnormally distributed data, respectively. Categorical
variables were summarized as percentages and chi-square test was
applied for statistical comparisons. A multivariate logistic regression
model was used to assess the independent association of NLR with
CTFC and in-hospital mortality. Odds ratio (OR) with 95% conﬁdence
intervals (95% CI) were calculated. A Kaplan–Meier curve was used to
plot the 12-month outcomes of the tertiles, and a log-rank test was
applied to assess signiﬁcance across the tertiles. Receiver operating
characteristic (ROC) curves were performed to reveal threshold value
of NLR that could be used to predict mortality. A p-value < 0.05
was considered statistically signiﬁcant. Statistical comparisons were
performed using SPSS version 18 (SPSS Inc., Chicago, IL, USA).
Results
Basic characteristics of the patients
Of all the patients recruited in the study, 636 cases (100%) and
546 cases (86%) were available for in-hospital and 12-month
follow-up data, respectively. Patients’ baseline characteristics are
listed in Table 1. The patients were stratiﬁed into three tertiles
according to their NLRs upon admission (tertile I < 3.0, tertile II
3.0–6.40, tertile III > 6.40). There were 212 patients in each tertile
with mean age 59.50  11.17 years, 78.8% men in tertile I, mean age
Table 1
Basic characteristics of patients.
Variable Tertile
I (<3.0) II (3.0–6.40) III (>6.40) p value
(n = 212) (n = 212) (n = 212)
Age (years) 59.50  11.17 59.22  11.29 59.13  12.00 0.941
Men 167 (78.8%) 163 (76.9%) 165 (77.8%) 0.896
Duration from symptom onset to recanalization (h) 4.830 (3.170–9.628) 5.500 (4.000–9.500) 6.460 (4.500–10.628) 0.614
Hypertension 95 (44.8%) 111 (52.4%) 103 (48.6%) 0.299
Diabetes mellitus 31 (14.6%) 31 (14.6%) 38 (17.9%) 0.320
Smoking 121 (58.7%) 138 (65.1%) 120 (58.3%) 0.277
Drinking 32 (15.1%) 28 (13.2%) 27 (12.7%) 0.756
Systolic pressure on admission (mmHg) 131.72  26.30 129.09  25.53 125.51  25.11 0.048
Heart rate on admission (min1) 71.02  16.44 73.94  19.30 80.11  20.56 <0.001
Peak CK-MB (U/L) 164.17  137.02 204.25  178.83 261.17  226.61 <0.001
Hs-CRP (mg/L) 25.58  26.62 32.39  39.36 44.12  53.16 <0.001
GFR (mL/min/1.73 m2) 87.53  22.29 86.79  22.24 88.03  25.57 0.864
LVEF on admission (%) 51.50  8.98 50.35  9.60 49.31  9.21 0.055
Total cholesterol (mmol/L) 5.04  1.17 5.01  1.21 4.76  1.08 0.026
Total triglyceride (mmol/L) 1.87  1.20 1.67  0.87 1.65  1.07 0.053
HDL (mmol/L) 1.15  0.26 1.19  0.27 1.19  0.31 0.172
LDL (mmol/L) 3.37  1.15 3.33  1.21 3.02  0.96 0.003
Lipoprotein a (mg/dL) 28.15  19.13 26.40  19.16 29.81  21.11 0.229
WBC (109/L) 9.21  2.61 10.42  2.96 12.00  3.48 <0.001
Neutrophil (109/L) 5.35  1.69 7.88  2.27 10.48  3.10 <0.001
Lymphocyte (109/L) 3.07  1.35 1.78  0.54 1.13  0.39 <0.001
Monocyte (109/L) 0.53  0.30 0.53  0.35 0.54  0.42 0.955
Hemoglobin (g/L) 146.21  16.39 145.95  17.64 145.75  19.39 0.965
Platelet (109/L) 215.67  58.75 214.06  59.87 212.38  54.29 0.841
Temporary pacemaker 71 (33.5%) 87 (41.0%) 70 (33.0%) 0.155
Intra-aortic balloon pump 2 (0.94%) 4 (1.9%) 6 (2.8%) 0.361
Thrombus aspiration 50 (23.6%) 47 (22.2%) 50 (23.6%) 0.995
Infarct-related coronary artery
Left anterior descending 107 (50.5%) 99 (46.7%) 113 (53.3%) 0.394
Left circumﬂex 21 (9.9%) 23 (10.8%) 26 (12.3%) 0.737
Right coronary artery 84 (39.6%) 93 (43.9%) 81 (38.2%) 0.466
Number of coronary arteries narrowed
>1 155 (73.1%) 167 (78.8%) 162 (76.4%) 0.390
Use of medicine in hospital
Aspirin 192 (90.6%) 189 (89.2%) 195 (92.0%) 0.608
Statin 197 (92.9%) 193 (91.0%) 201 (94.8%) 0.317
ACEI/ARB 109 (47.2%) 103 (48.6%) 115 (54.2%) 0.305
b-Blocker 122 (57.5%) 137 (64.6%) 136 (64.2%) 0.244
Spironolactone 172 (81.1%) 166 (78.4%) 173 (81.6%) 0.652
CTFC 16.17  6.46 21.44  11.25 25.04  14.88 <0.001
CTFC  40 1 (0.5%) 9 (4.2%) 22 (10.4%) <0.001
In-hospital MACE
Arrhythmia 37 (17.5%) 42 (19.9%) 57 (26.9%) 0.049
Heart failure 38 (17.9%) 36 (17%) 42 (19.8%) 0.744
Angina 23 (10.8%) 35 (16.5%) 44 (20.8%) 0.020
In-hospital mortality 2 (0.9%) 5 (2.4%) 14 (6.6%) 0.003
Mortality out of hospital follow-up 12 months 7 (3.3%) 12 (5.7%) 24 (11.0%) 0.005
Data are expressed as mean  SD for continuous variables or percentage (%) for categorical variables.
CK-MB, creatinine kinase-MB; hs-CRP, high sensitivity C-reactive protein; GFR, glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; WBC, white blood cells; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CTFC, corrected thrombolysis in
myocardial infarction frame count; MACE, major adverse cardiovascular event.
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59.13  12.00 years, 77.8% men in tertile III, respectively. Age and
gender were not statistically different across tertiles (p = 0.941 and
p = 0.896, respectively). Besides, the duration from symptom onset to
recanalization for group tertile I was 4.830 h (3.170–9.628), group
tertile II was 5.500 h (4.000–9.500), and group tertile III was 6.460 h
(4.500–10.628), respectively. There was no obviously signiﬁcant
difference among the three groups.
Correlation between NLR and the traditional clinical risk factors of
myocardial infarction
As shown in Table 1, NLR, regardless of the use of invasive
procedures or standard medical therapy, was observed to be
correlated with several traditional clinical risk factors. Patients
with higher NLRs were more likely to have increased hs-CRP, WBC,peak creatinine kinase-MB (CK-MB), and heart rates (p < 0.001,
p < 0.001, p < 0.001, and p < 0.001, respectively), and decreased
total cholesterol (TC), low-density lipoprotein (LDL) levels and
systolic blood pressure (SBP) (p = 0.026, p = 0.003, and p = 0.048,
respectively).
NLR is correlated with CTFC
Moreover, we observed that patients in tertile III had increased
CTFC compared with those in tertile II and I [25.04  14.88 (III),
21.44  11.25 (II), 16.17  6.46 (I), p < 0.001; Table 1]. Further
analysis revealed that a positive correlation was found between CTFC
and NLR (r = 0.517, p < 0.001, Table 2 and Fig. 1). CTFC was also
correlated with glomerular ﬁltration rate (GFR), WBC, neutrophil,
lymphocyte, and NLR (p = 0.004, p < 0.001, p < 0.001, and p < 0.001,
respectively; Table 2).
Table 2
Correlation between the baseline clinical data and CTFC as well as in-hospital
mortality.
Variable CTFC in-hospital mortality
r p-Value r p-Value
Age (years) 0.273 0.085 0.21 0.802
Systolic pressure on admission (mmHg) 0.280 0.063 0.316 0.004
Heart rate on admission (min1) 0.244 0.304 0.235 0.377
Left ventricular ejection fraction
on admission (%)
0.209 0.839 0.28 0.045
Peak CK-MB (U/L) 0.257 0.184 0.205 0.895
Hs-CRP (mg/L) 0.268 0.111 0.294 0.018
GFR (mL/min/1.73 m2) 0.322 0.004 0.334 0.001
Total cholesterol (mmol/L) 0.267 0.119 0.282 0.039
LDL (mmol/L) 0.271 0.097 0.297 0.015
WBC (109/L) 0.357 <0.001 0.264 0.110
Neutrophil (109/L) 0.458 <0.001 0.284 0.035
Lymphocyte (109/L) 0.418 <0.001 0.323 0.002
NLR 0.517 <0.001 0.439 <0.001
CK-MB, creatinine kinase-MB; hs-CRP, high sensitivity C-reactive protein; GFR,
glomerular ﬁltration rate; LDL, low-density lipoprotein; WBC, white blood
cells; NLR, neutrophil/lymphocyte ratio; CTFC, corrected thrombolysis in
myocardial infarction frame count. Fig. 2. Long-term survival rates among patients from different tertiles. Patients
were categorized into three tertiles according to neutrophil/lymphocyte ratio upon
admission (tertile I < 3.0; tertile II 3.0–6.40; tertile III > 6.40).
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Aside from CTFC, NLR was also strongly correlated with in-
hospital and long-term mortality. There were 21 in-hospital
deaths, and 43 deaths in total over the follow-up period. The causes
for in-hospital deaths were complications after myocardial
infarction and cardiac death, such as heart failure, malignant
arrhythmias, and cardiac shock. The 43 late deaths after discharge
were all-cause mortality. Correlation between NLR and in-hospital
mortality was ﬁrst analyzed and turned out to be strongly
correlated with r = 0.439 and p < 0.001 (Table 2). Among patients
who survived hospital discharge, 11.0% of mortality in the 12-
month follow-up was observed in tertile III (n = 24), compared
with 5.7% (n = 12) in tertile II, and 3.3% (n = 7) in tertile I,
respectively (p = 0.005). The major separation between the
Kaplan–Meier curves was observed during the third months of
follow-up (Fig. 2). Positive trends between NLR and in-hospital and
long-term mortality were supported by monotonic increases in
the percentage of deaths from tertile I to tertile III (p = 0.003 and
p = 0.005, respectively; Table 1).
NLR is an independent predictor of CTFC and in-hospital mortality
Variables associated with CTFC and mortality were analyzed
using multivariate logistic regression (Tables 3 and 4). On
multivariate regression, NLR (OR 2.031 per unit increase, 95% CI:
1.627–2.435, p < 0.001) and heart rate on admission (OR 0.932 perFig. 1. Correlation between corrected thrombolysis in myocardial infarction frame
count (CTFC) and neutrophil/lymphocyte ratio (NLR).unit decrease, 95% CI: 0.878–0.986, p = 0.017) remained indepen-
dent predictors of CTFC after PCI (Table 3). NLR (OR 1.176 per unit
increase, 95% CI: 1.025–1.351, p = 0.021) was demonstrated as
an independent predictor of in-hospital mortality (Table 4).
Fig. 3 shows that threshold value of NLR was 5.9 (sensitivity:
63.7%, speciﬁcity: 61.1%) for predicting in-hospital mortality
(AUC = 0.607, 95% CI: 0.475–0.739, p = 0.253). Taken together,
NLR was shown to be an independent predictor of coronary blood
ﬂow and in-hospital mortality.
Discussion
The results of the current study indicate that: (1) NLR could
predict coronary blood ﬂow in patients with STEMI undergoing
PCI; (2) NLR acted as a potent independent risk factor for in-
hospital mortality; (3) NLR also appeared to have some implica-
tions for long-term mortality.
Inﬂammation has been reported to be involved in the initiation,
development, and rupture of atherosclerotic plaque; therefore
inﬂammation markers have been widely studied as predictors of
CVDs. Leukocyte counts and traditional risk factors have been used
in the diagnosis of coronary artery disease (CAD) [18]. Studies have
also found that total WBC count acted as an independent risk
factor for CAD [19,20]. Neutrophil and lymphocyte counts have
also been studied as inﬂammation markers [21].
Of note, NLR, due to its potential as predictors for various
diseases, has been received much attention in the ﬁeld of CVD
[8,16,22–24]. NLR reﬂects the balance between neutrophil and
lymphocyte levels in the blood. Compared to other inﬂammatory
markers, NLR is a simpler and less expensive diagnosis indicator. It
has been observed that NLR demonstrated a certain value in the
diagnosis and prognosis of acute coronary syndrome [25], angina
[24], the severity of CAD [22,26], long-term prognosis in acute
decompensated heart failure [27] as well as some other non-
cardiac disorders [23,28]. Cho’s group investigated the combina-
tion use of hemoglobin level and NLR for risk evaluation in
patients with STEMI undergoing primary PCI. Their results
showed that the combination of hemoglobin level and NLR could
predict short-term clinical outcome. However, their study failed
to show any correlation between NLR and coronary blood ﬂow
[29]. In our current study, by measuring CTFC and potentially
related factors in blood, we demonstrated that NLR was an
Table 3
Effects of multiple variables on CTFC in univariate and multivariate logistic regression analysis.
Variable Unadjusted OR 95% CI p-Value Adjusted OR 95% CI p-Value
Systolic pressure on admission (mmHg) 0.977 0.940–1.014 0.222 0.996 0.960–1.032 0.820
Heart rate on admission (min1) 0.974 0.919–1.029 0.347 0.932 0.878–0.986 0.017
Hs-CRP (mg/L) 1.023 0.997–1.048 0.086 1.002 0.976–1.027 0.876
Total cholesterol (mmol/L) 0.499 0.381 to 1.378 0.266 0.914 0.842 to 2.671 0.307
LDL (mmol/L) 0.454 0.450 to 1.368 0.324 0.777 1.050 to 2.604 0.404
WBC (109/L) 1.821 1.500–2.143 <0.001 1.328 0.510–2.145 0.497
Neutrophil (109/L) 2.741 2.423–3.059 <0.001 1.168 0.255–2.081 0.739
Lymphocyte (109/L) 0.102 0.743 to 0.947 0.813 0.408 0.905 to 1.720 0.542
NLR 2.659 2.422–2.896 <0.001 2.031 1.627–2.435 <0.001
CTFC, corrected thrombolysis in myocardial infarction frame count; hs-CRP, high sensitivity C-reactive protein; LDL, low density lipoprotein; WBC, white blood cells; NLR,
neutrophil/lymphocyte ratio; CI, conﬁdence interval; OR, odds ratio.
Table 4
Effects of various variables on in-hospital deaths in univariate and multivariate logistic regression analysis.
Variable Unadjusted OR 95% CI p-Value Adjusted OR 95% CI p-Value
Systolic pressure on admission (mmHg) 0.974 0.957–0.992 0.005 0.977 0.957–0.998 0.029
Heart rate on admission (min1) 1.006 0.984–1.028 0.613 0.981 0.960–1.002 0.075
Hs-CRP (mg/L) 1.009 1.002–1.015 0.012 1.005 0.994–1.016 0.406
Total cholesterol (mmol/L) 0.700 0.445–1.103 0.124 0.915 0.355–2.356 0.854
LDL (mmol/L) 0.661 0.417–1.049 0.079 0.585 0.215–1.591 0.294
WBC (109/L) 1.098 0.976–1.236 0.118 1.068 0.697–1.637 0.763
Neutrophil (109/L) 1.151 1.027–1.291 0.016 0.878 0.554–1.392 0.581
Lymphocyte (109/L) 0.432 0.221–0.846 0.014 0.857 0.341–2.155 0.743
NLR 1.159 1.082–1.242 <0.001 1.176 1.025–1.351 0.021
Hs-CRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; WBC, white blood cells; NLR, neutrophil/lymphocyte ratio; CI, conﬁdence interval; OR, odds
ratio.
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with STEMI undergoing primary PCI. Besides, our results also
indicated that CTFC was correlated with GFR, WBC, neutrophil
count and lymphocyte count.
There are also a few studies that investigated the value of NLR in
predicting mortality in patients with CVD. Papa et al. conducted a
3-year follow-up study for patients who had CAD. Their study
revealed that NLR was able to predict cardiac mortality in patients
with stable CAD [15]. An 8-year follow-up study of STEMI patients
accomplished by Shen et al. showed that there was a relation
between NLR and long-term mortality. But their study measured
the NLR in the ﬁrst three days of STEMI, which could be affected by
various factors during the in-hospital period [30]. Duffy and
colleagues found out that pre-procedural NLR was correlated with
increased risk of long-term mortality in patients undergoing
primary PCI. However, they failed to specify the characteristics ofFig. 3. Receiver operating characteristic (ROC) curves of neutrophil/lymphocyte
ratio.the study population [11]. In our study, blood samples were
collected immediately after admission for analysis of NLR, etc. and
patients were well characterized. And our results revealed that NLR
is an independent predictor for in-hospital mortality in patients
with STEMI undergoing PCI.
Taken together, by analyzing the correlation between NLR with
coronary blood ﬂow and in-hospital as well as long-term mortality
in 636 patients with STEMI undergoing PCI, our results showed
that NLR was an independent risk factor for coronary blood ﬂow as
well as in-hospital mortality. Of note, further study, although
beyond the scope of this study, is warranted to investigate the
relationship between NLR and coronary blood ﬂow and short-term
and long-term mortality in patients with STEMI undergoing PCI
based on a larger sample size from a multicenter database.
Conclusion
NLR, an indicator that can be tested in the laboratory with low
cost and time consumption, is independently correlated to
coronary blood ﬂow and acts an independent risk factor for in-
hospital mortality in patients with STEMI undergoing PCI.
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